Pharmacogenomics – Implications in the Development of HIV-Associated Brain Disease

Title: Pharmacogenomics – Implications in the Development of HIV-Associated Brain Disease

Volume: 8 Issue: 2

Author(s): Thorsten Nolting and Gabriele Arendt

Affiliation:

Keywords: HIV, CNS, pharmacogenomics, pharmacogenetics, MMP9, SLC, ABC-transporter, cytochrome

Abstract: Pharmacogenomics is a relatively new field in HIV-research, especially when neurological issues are concerned. Influence of polymorphisms in CYP3A4, CYP2B6, CYP2D6, ABCB1, ABCG2, ABCC4, SLC22, SLC28, SLC29 and MMP9-genes on pharmacokinetic data is discussed in the article. Due to the lack of published studies, but promising results in the few existing publications, scientists should be encouraged to integrate neurological aspects in pharmacogenomics research.

Cite this article as:

Nolting Thorsten and Arendt Gabriele, Pharmacogenomics – Implications in the Development of HIV-Associated Brain Disease, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (2) . https://dx.doi.org/10.2174/187152309789152101